Zydus Lifesciences enterprise value

Share price at each year-end

Tap a line for its trend	Currentlast 12M	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus


1,18,255	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
6,631	6,631	5,678	666	1,107
2,471	2,471	2,405	2,272	2,173
11,770	11,770	3,170	769	1,163
1,25,865	—	—	—	—
5,139	5,139	−2,508	103	56.1
₹1,251.14	—	—	—	—

41,352	41,352	29,528	22,870	20,852
28.5%	28.5%	10.7%	3.4%	5.6%
0.09×	—	—	—	—

4.40×	—	—	—	—
15.14×	—	—	—	—
19.10×	—	—	—	—
28,592	27,148	23,242	19,547	17,237
8,316	8,475	7,059	5,384	3,860
6,591	7,067	6,143	4,620	3,137
—	2,117	6,777	3,228	2,689
−1,277	−1,277	5,064	2,321	1,658
—	−1,363	5,043	2,306	1,629
—	3,394	1,713	907	1,031

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

ZYDUSLIFE₹1,175.50

Zydus Lifesciences Ltd.

· Pharma & Health

₹ CrorePeersSUNPHARMA DRREDDY CIPLA TORNTPHARM DIVISLAB MAXHEALTH APOLLOHOSP AUROPHARMAMcap ₹1.18L Cr

HighlightsEnterprise Value Multiples Per ShareAnnuals · FY-end closes

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Current/LTM TTM · last close
Market Capitalization	—	—	—	—	1,18,255.3
- Cash, Equiv & ST Investments	1,107.1	665.5	5,677.9	6,631.0	6,631.0
+ Minority Interest	2,172.5	2,272.1	2,405.3	2,470.8	2,470.8
+ Total Debt	1,163.2	768.6	3,169.5	11,769.5	11,769.5
Enterprise Value	—	—	—	—	1,25,864.6
Net Debt (memo)	56.1	103.1	-2,508.4	5,138.5	5,138.5
EV per Share	—	—	—	—	1,251.14

Total Capital	20,851.5	22,870.2	29,527.9	41,351.7	41,351.7
Total Debt/Total Capital	5.58	3.36	10.73	28.46	28.46
Total Debt/EV	—	—	—	—	0.09

EV/Sales	—	—	—	—	4.40
EV/EBITDA	—	—	—	—	15.14
EV/EBIT	—	—	—	—	19.10
Reference Items — Trailing FY Values
Sales	17,237.4	19,547.4	23,241.5	27,148.4	28,591.7
EBITDA	3,859.9	5,384.3	7,058.5	8,475.1	8,316.0
EBIT	3,137.2	4,620.2	6,142.7	7,067.1	6,591.4
Operating Cash Flow	2,688.8	3,227.9	6,776.7	2,116.6	—
Free Cash Flow	1,657.9	2,321.3	5,064.1	-1,277.4	-1,277.4
FCFF (free cash flow to the firm)	1,629.3	2,306.5	5,043.1	-1,362.6	—
Capital Expenditure	1,030.9	906.6	1,712.6	3,394.0	—

Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.